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Advances and Future Challenges in Adenoviral Vector Pharmacology and
Targeting
Reeti Khare1, Christopher Y. Chen2, Eric A. Weaver2 and Michael A. Barry2,3,*
1

Virology and Gene Therapy Program, Mayo Graduate School, 2Department of Medicine, Division of Infectious Diseases, Translational Immunovirology and Biodefense Program, 3Department of Molecular Medicine, Department of
Immunology, Mayo Clinic, Rochester, MN 55905, USA
Abstract: Adenovirus is a robust vector for therapeutic applications, but its use is limited by our understanding of its
complex in vivo pharmacology. In this review we describe the necessity of identifying its natural, widespread, and multifaceted interactions with the host since this information will be crucial for efficiently redirecting virus into target cells. In
the rational design of vectors, the notion of overcoming a sequence of viral “sinks” must be combined with re-targeting to
target populations with capsid as well as shielding the vectors from pre-existing or toxic immune responses. It must also
be noted that most known adenoviral pharmacology is deduced from the most commonly used serotypes, Ad5 and Ad2.
However, these serotypes may not represent all adenoviruses, and may not even represent the most useful vectors for all
purposes. Chimeras between Ad serotypes may become useful in engineering vectors that can selectively evade substantial viral traps, such as Kupffer cells, while retaining the robust qualities of Ad5. Similarly, vectorizing other Ad serotypes
may become useful in avoiding immunity against Ad5 altogether. Taken together, this research on basic adenovirus biology will be necessary in developing vectors that interact more strategically with the host for the most optimal therapeutic
effect.

Keywords: Ad serotypes, liver, sequestration, serotypes, targeting.
INTRODUCTION
Adenoviruses (Ads) are icosahedral non-enveloped DNA
viruses with diameters approximately 90 to 100 nm (Fig. 1).
Ads were first isolated from human adenoids in 1953 and
since then, bovine, ovine, murine, canine, equine, porcine,
and caprine specific strains have also been identified [1].
With over 50 currently recognized human serotypes, Ads are
widely present in human populations (Table 1). These viruses are typically associated with mild disease, however
more severe complications may occur in infants or in immunocompromised patients. Most Ad serotypes manifest
with mild respiratory symptoms, although others have various pathologies like acute respiratory disease (Ad3, 4, 7, 14,
21), keratoconjunctivitis (Ad8, 9, 10, 19), gasteroenteritis
(Ad40, 41), and even obesity (Ad36) [2-4].
Adenoviruses have several features that make them inherently useful as oncolytic, vaccine, or gene therapy vectors. For instance, they are non-enveloped viruses and are
therefore sufficiently stable for packaging as lyophilized
preparations in vials or capsules, even without a cold chain.
They mediate high transduction efficiency in non-dividing
(i.e. most human somatic cells) and dividing cells (i.e. transformed cells) and can generate 104 virus particles (vp) per
infected cell. This supports large-scale preparations of 1013
vp from 109 cells.
Ad genomes range from ~36-40 kilobase pairs (kb) in
length and can carry large transgenes up to this size. Their
*Address correspondence to this author at the Mayo Clinic, 200 First Street
SW, Rochester, MN 55902; USA; Tel: 507-266-9090; Fax: 507-255-2811;
E-mail: mab@mayo.edu
1566-5232/11 $58.00+.00
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DNA genome and high fidelity DNA polymerase confers
relative genomic stability in comparison to RNA viruses.
Furthermore, unlike retroviruses, Ad genomes are nonintegrating. While this poses minimal risk for insertional
mutagenesis [5] these vectors are comparatively ineffective
for the genetic modification of dividing cells since cell division will result in loss of the transgene [6, 7]. On the other
hand, Ad genomes can persist for years in non-dividing cells
provided that an immune response is not produced against
Ad or the transgene product.
When applied as a gene therapy agent, intravenous delivery of Ad5 into mice produces supraphysiologic levels of its
transgene. For example, in vivo genetic modification of mice
with Ad5 resulted in 6 mg/ml of 1-antitrypsin in the circulation; these are levels at which the transgene became the
second most abundant protein in the blood [8]. In other
words, when Ad has been applied as a gene-based vaccine it
is one of the most robust platforms.
While Ads are potent in vivo gene delivery platforms,
they are also robust at generating immune responses. For
example, a head to head comparison with vaccinia virus vectors or plasmid DNA vaccines in non-human primates demonstrated that Ad mediated the most robust immune responses [9]. This effect is fortuitous for vaccine purposes,
but is problematic for gene therapy approaches. For instance,
pre-existing immunity against the virus or the transgene protein reduces the persistence of genetic correction [5-7, 10, 11].
This review is an update and expansion of a previous
review by our laboratory that was published in 2007 ([12]
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2244792/).
© 2011 Bentham Science Publishers Ltd.
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Fig. (1). Schematic of Ad capsid structure. (a) Cryo-electron micrograph reconstruction of the Ad5 capsid. The dotted triangle overlays
one of the 20 facets of the icosahedron. (b) Diagram of the adenoviral capsid showing a "group of nine" hexon trimers, penton bases, and
fiber n-terminus that is observed in cryo-EM. (c) Addition of flexible fiber structures to B that are not observed in cryo-EM.

This earlier review provided a comprehensive discussion of
Ad protein composition, structure, and life cycle. It also integrated applications of basic Ad biology in terms of vector
targeting and strategies for vector improvement, such molecular linkers, genetic, and chemical modifications with a
particular emphasis on modification of the Ad fiber protein
for targeting efforts. The 2007 review was also Ad5-centric,
focusing on the most utilized adenoviral serotype for gene
therapy.
Table 1.

Classification of Human Adenoviral Serotypes [37,
195]

Species

Serotype

A

12, 18, 31

B

3, 7, 11, 14, 16, 21, 34, 35, 50, 55

C

1, 2, 5, 6

D

8, 9, 10, 13, 15, 17, 19, 20, 22, 23, 24, 25, 26, 27,
28, 29, 30, 32, 33, 36, 37, 38, 39, 42, 43, 44, 45, 46,
47, 48, 49, 51, 53, 54

E

4

F

40, 41

G

52

In this update, we have incorporated recent information
of Ad vector biology and targeting as it stands in 2011. In
particular, we address the growing understanding of in vivo
virus pharmacology rather than in vitro virus-cell biology.
We discuss the biology of Ad5 and other Ad serotypes in
vivo with particular emphasis on the known and speculated
pharmacology “sinks” for these viruses that affect their use
for systemic or targeted therapy. This review will also discuss recent observations regarding the role of the Ad hexon

protein on in vivo (but not in vitro) virus tropism and how
recent engineering efforts have been directed more at adenovirus “detargeting” than adenovirus “retargeting”. With detargeting of significant pharmacologic sinks nearly at hand,
the field will now likely be able to apply the retargeting
strategies that appeared promising in vitro, but that have historically failed in vivo.
ADENOVIRUS SPECIES AND SEROTYPES
Adenoviruses were originally defined by a number of
bioassays including cross-susceptibility to neutralizing antibodies and subsequent categorization into serotypes. With
the advent of DNA sequencing, newer viruses are now being
characterized by genotype and phylogenetic comparisons to
other Ad genomes (Fig. 2 and see [13] for an excellent review). Current convention is to describe distinct Ads as new
serotypes although they are now typically classified by genotyping.
Based on serotyping, related human and non-human Ads
were formerly referred to as subgroups. With the advent of
more sequence data, this designation has been revised to
describe the different groups as species. There are currently
55 human adenovirus serotypes that distribute into seven
species from A to G (Table 1) [14]. As of this writing only
34 full genome sequences are available for full genome
comparison (Fig. 2). The vast majority of data on the biology
of Ads has been garnered using species C adenoviruses Ad2
and Ad5 in cell culture. Therefore, most knowledge of viruscell interactions is based largely on two out of now 55 human Ad serotypes. While many lessons learned with Ad2
and Ad5 will still apply to other Ads, many others do not
apply.
More recently, a variety of groups have delved into the
biologies of other human and non-human Ads in the quest
for new functionalities or to evade anti-Ad5 immunity in
patients [15-23]. In this review, we describe some aspects of
novel Ad biologies that vary between species and serotypes.
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For additional information, see several reviews on different
Ad serotypes [10, 24-26].
Ad34
Ad11
Ad35
Ad55
Ad14
Ad16
Ad7
Ad3
Ad21
Ad50

Ad4
Simian Ad25

B

E

-G

Ad52
Ad40
Ad41
Ad18
Ad12
Ad31
Ad5
Ad1
Ad6
Ad2

F
A

C

Ad8
Ad54
Ad9
Ad26
Ad28
Ad49
Ad48
Ad46
Ad17
Ad22
Ad53
Ad37
Ad19

D

0.1

Fig. (2). Phylogenetic Tree of Human Adenoviruses. Full genome comparison of 34 completed Ad sequences groups viruses
with species grouping according to genetic similarity.

NATURAL CELL BINDING AND ENTRY BY ADENOVIRUSES
In vitro, adenoviruses infect permissive host cells rapidly
and efficiently. Typical time from infection to the production
of new virions ranges from 14 to 19 hours depending on serotype [27]. Initial interactions with cellular receptors could
theoretically be mediated by any surface exposed protein on
the virus (Table 2 and see [12] http://www.ncbi.nlm.nih.gov/
pmc/articles/PMC2244792/) for background on virus structure/function). Early work in Ad interactions identified a
subset of proteins that interact with receptors in vitro (fiber,
penton base) and in vivo fiber, penton base, hexon, (Fig. 1).
As more of these interactions are revealed exposed, more
proteins will likely be found to interact directly or indirectly
with receptors and proteins under certain circumstances (see
interactions of hexon with blood factors below).
Adenovirus Major Capsid Proteins
There are three major capsid proteins on adenoviruses:
fiber, penton base, and hexon (Fig. 1). There are 36 monomers of fiber, 60 monomers of penton base, and 720 monomers of hexon on each Ad virion. There is good evidence
that the fiber and penton base proteins of many Ad serotypes
interact directly with cellular receptors. In contrast, there is
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little evidence showing that hexons display a ligand for cellular receptors. The massive number of hexons per virion
certainly has the possibility of mediating avidity interactions
via multivalent charge interactions. However, a high affinity
evolved ligand has not been associated with Ad5 or any Ad
hexon to date.
Under the simplest circumstances on permissive cells, the
Ad fiber protein acts as the primary high affinity attachment
protein for the virus in vitro, provided its receptor is expressed on cells. Three fiber monomers trimerize to form an
antenna-like structure located at each vertex of the icosahedral capsid (Fig. 1C). The tail domain of the trimer attaches
directly to penton; the shaft length is determined by multiple
amino acid repeats; the knob domain confers specificity to
cellular receptors.
Although fibers across the seven human Ad species have
the same basic structure, their amino acid sequences and
shaft lengths vary considerably. Prototype Ad5 fiber binds to
CAR, the coxsackie and adenovirus receptor (reviewed in
[12, 25]). Viruses from other species can bind to CAR,
CD46, sialic acid, desmoglein-2, and perhaps other receptors
[25, 28].
In vitro, Ad5 binds CAR and also binds to cellular v
integrins [29]. Ad5 binds CAR with 15 nM affinity, whereas
penton base engages integrins with 10-fold lower affinity
[29]. Because of this affinity difference, species C viruses
have been shown to first engage CAR and then rapidly transition to binding and entry via interaction with integrins [30].
This dual receptor utilization is made possible by the length
and flexibility of the Ad5 fiber (Fig. 1C). Ad5 has one of the
longest fiber proteins with 21 -spiral repeats in its shaft [31]
(sometimes referred to as having 22 repeats [25]).
Exactly how Ad5 could transition from binding CAR to
binding integrins was unclear until it was realized that its
fiber is able to bend due to a flexible lysine-lysine-threoninelysine (KKTK) motif at repeat three in its shaft ([32] and Fig
1C). This flexibility can be appreciated in cryo-electron microscopic (cryo-EM) reconstructions of Ad5 for although
they are one-third the diameter of the icosahedron, the
twelve 35 nm fibers are not observed. Instead, only a stump
of the fiber can be seen (Fig. 1A) [33, 34]. This loss of fiber
electron density results from the computational assembly and
integration of hundreds of the images of individual Ad virions during cryo-EM image reconstruction. Proteins like
hexon, that are fixed in space on the virion resolve into structures (Fig. 1A). If the proteins are flexible, then they will be
in a different orientation with respect to the virion. When this
is averaged between hundreds of virions, these mobile Ad5
fiber proteins disappear. In contrast, when short-shafted fibers that lack this flexible KKTK domain are imaged, their
shafts can be observed [35]. Fibers also have an additional
flexibility motif between the fiber shaft and knob domain
([31] and Fig. 1C). This can be inferred in cryo-EM using
short-shafted Ad35 fiber, since its shaft is observed, but its
knob is not [35].
This flexibility allows the long-limbed Ad5 to undergo
"virus yoga" [32] wherein the fiber knob binds CAR and
then the shaft flexes to allow an arginine-glycine-aspartic
acid (RGD) motif on penton to bind to v1, v3, v5 or
31 integrins on the cell surface [29]. Binding of RGD to
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Summary of Encapsidated Proteins in Adenovirus Serotype 5 [2, 33, 196-198]

Protein Number

Protein Name

Size (kDa)

Number Per Virion

Known Functions

II

Hexon monomer

110

720

Structural; liver tropism

III

Penton base

63

60

Structural; binds cellular integrins

IIIa

Cement protein

63

60

Associated with penton base

IV

Fiber

62

36

Primary attachment protein

V

Core protein

42

160

Associates with DNA and penton to connect the nucleocore and capsid

VI

Cement protein

23

~360

Endosomal lysis and escape; imports hexon into the nucleus for viral assembly

VII

Core protein

19

840

Histone-like

VIII

Cement protein

15

120

Associated with underside of hexon capsid;
Stabilization/assembly of particle?

IX

Cement protein

14

240

Stabilization/assembly of capsid

TP

Terminal Protein

55

2

Protein primer for genome replication

X

Mu

4

100

Nucleoprotein; Genome replication?

IV2a

Nucleoprotein
Protease

Genome packaging
23

~10-12

integrins triggers Ad5 internalization via receptor-mediated
endocytosis on clathrin-coated pits. The virions are subsequently able to escape from endosomes and traffic to the
nucleus within 30 to 60 minutes of cell binding on permissive cells (reviewed in [12]). If the fiber receptor is absent or
if CAR binding is ablated on knob, the virus can bind more
slowly by lower affinity interaction of penton base with integrins. In this circumstance in vitro, short (1 hour) exposure
of CAR-negative cells with Ad5 results in poor transduction
whereas longer (24 hour exposure) can mediate very high
transduction (e.g. Ad5 on K562 cells [36] and data not
shown). If cells lack CAR and integrins, they are relatively
(but not absolutely) resistant to Ad5 infection.
This in vitro infection paradigm is based on Ad5 and Ad2
infection in cell culture. These rules apply to some extent to
other Ad species and serotypes with some minimal to drastic
variations. For example, other species C Ads behave
similarly to Ad5 in vitro, although the fiber of Ad6 is three
repeats shorter – perhaps making its yoga process somewhat
less efficient [37]. In contrast, most other species of human
Ads have markedly shorter fibers than Ad5 (with only 6 or 8
shaft repeats) creating a disconnect between being flexible
enough to bind a receptor and being able to use a receptor for
cell infection. These shorter shafted fibers may target receptors that are directly endocytosed such that integrin interactions are less important.
For example, the fiber for species D Ad37 can bind to
CAR, CD46, and sialic acid. However, it appears only able
to use sialic acid as a receptor for infection [18, 38, 39]. This
effect may be due to the very short length of species D fibers

Viral protein processing and maturation

with only 8 -spiral repeats. These fibers may lack sufficient
flexibility or length to allow functional combination receptor
utilization such as Ad5 can perform between CAR and integrins. Similar effects are observed with short species B
viruses Ad35 that have fibers with only 5.5 repeats. These
viruses are able to use CD46 or other receptors efficiently
with these shorter shafts [40]. However, if CAR-utilizing
viruses are given short shafts, this abrogates effective combination of CAR and integrin and infectivity is markedly
reduced.
Short-shafted fibers may also enable Ads to use integrins
more efficiently as primary receptors. For example, comparison of species D Ad8, 9, 19, 19a, and 37 demonstrated that
Ad8, 19a, and 37 use sialic acid as a functional receptor,
whereas Ad9 and19 appeared to use v integrins as their
primary receptor in vitro [38]. In our recent screen of species
D Ads for infection of B cell cancers, we observed that most
were largely independent of sialic acid for infection, but instead used a combination of CD46 and v integrins for infection and killing [41]. Therefore, longer fibers appear to create more steric hindrance with penton-integrin interactions
and may require more flexibility. In contrast, shorter shafted
fibers may obstruct penton-integrin interactions to a lesser
extent and better use this infection pathway on cells.
ADENOVIRUS PHARMACOLOGY IN VIVO
Interactions with Blood Factors Impart Tropism
Given that both fiber and penton have receptor-binding
motifs, viruses with inactivating mutations were tested for
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"detargeting"[42]. While mutations to ablate CAR and integrin binding worked as expected in vitro, they had surprisingly weak effects on in vivo tropism [43, 44]. Subsequent
seminal work suggested that the difficulty in altering the
tropism of Ad5 was actually due to unexpected interactions
of the virus with host proteins in vivo [45]. Initial studies
indicated that Ad fiber can bind blood factors like FIX and
C4BP with moderate affinity [45]. However, later studies
independently concluded that hexon, not fiber, was the main
protein interacting with blood factors [46-48]. These studies
showed that factor X (FX) binds Ad5 hexon with nanomolar
affinity and that FX then targeted the virus to receptors on
hepatocytes. Comparison of FX binding to select Ads from
different Ad species demonstrated that approximately half of
the tested viruses bind FX [48].
Blood factors I to XIII and Protein C (PC) are produced
in the liver as zymogens and are activated by cleavage for
use in normal blood clotting. Vitamin K dependent blood
factors VII, IX, X and protein C enhance transduction of
Ad5 in vitro [45, 46]. These factors share the common domain structure GLA-EGF1-EGF2-SP, where SP is the catalytic serine protease domain, EGF1 and EGF2 are epidermal
growth factor-like domains, and the GLA domain is a hexonbinding glutamate rich domain [46, 47, 49, 50]. On the other
hand, non-homologous factors (FXI and FXII) do not enhance transduction [46]. Upon production in the liver, zymogens containing the GLA domain are carboxylated in a
vitamin K dependent manner on the -carbon of each of their
9-12 glutamic acid residues [24]. In vivo, physiologic levels
(8-10 μg/ml) of these -carboxylated blood factors results in
hepatocyte transduction even for CAR-ablated viruses. Conversely, inhibition of this post-translational vitamin K dependent -carboxylation with warfarin markedly decreases
hepatocyte transduction by Ad5 [46]. FX binding to hexon is
highly calcium dependent and can be inhibited by chelation
with EDTA. This is unsurprising, as the GLA domain binds
seven calcium ions, while the EGF1 and SP domains each
bind one. As a result, the absence of the GLA domain renders Ad5 unable to bind FX (as measured by surface Plasmon resonance) and thus unable to transduce hepatocytes
[47, 48].
Binding of the GLA domain of FX to Ad virions appears
to orient the SP domain of FX to bind heparan sulfate proteoglycans (HSPGs) on cells. After i.v. injection, this appears to yield selective infection of hepatocytes. However,
HSPGs are ubiquitously found on the cell surface and on
extracellular matrix proteins, so the mechanism of specific
uptake into hepatocytes is unclear. Recently, Bradshaw et al.
showed evidence that a high level of N- or O-sulfation (“sulfation signature”) on heparan sulfate in the liver is necessary
for FX mediated Ad infection, thus accounting for liver
specificity [51]. In addition, the fenestrated vasculature of
the liver provides easy access to hepatocytes as opposed to
other tissues where these “windows” are not present.
Ads display seven hypervariable region (HVR) domains
on their hexon proteins that vary in sequence between serotypes [52] and are primary targets for neutralizing antibodies
[53, 54]. Variations in these HVRs appear to correlate with
FX binding affinity and with the ability of Ad serotypes to
transduce hepatocytes [47]. Cryo-electron microscopy of
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Ad5 identified FX density near the central depression of the
hexon trimers near the HVRs [47, 48]. Mutational analyses
of Ad5 hexon suggested interactions of FX with HVR5 and 7
[55]. More precisely, a point mutation of glutamic acid 451
that is conserved in FX binders partially abolished binding of
FX to the virus [55].
These data suggest roles for HVR5 and 7 in FX binding.
However, even within Ad5's own species C viruses, there is
marked variation in liver transduction; Ad5 and Ad6 are
most robust and Ad1 and Ad2 are markedly less effective
[37]. When the HVRs of these viruses are compared, only
the HVR1 and 4 genotypes cluster with the higher liver
transduction phenotype. This is interesting given that the
HVR1s of Ad5 and Ad6 have considerable negative charge
(net negative charge of 13 and 8). At the same time, the GLA
domain of FX displays 7 or more Ca2+ and ions, it is interesting to speculate that binding or perhaps initial docking of FX
with hexon may be facilitated by FX interaction with HVR1.
Given that HVR1 is unstructured in x-ray crystals, interactions with this loop cannot be modeled easily. Therefore,
targeted mutation of HVR1 has not yet been tested.
These observations induced a paradigm shift in Ad biology by demonstrating that in vivo tropism of some Ads is
mediated not just by ligands on the virus, but also by host
factors. This showed that Ad5 is an excellent choice of vector for liver-directed gene therapy as it has natural tropism to
the liver upon systemic injection and can transduce hepatocytes with high efficiency. Conversely, Ad5 may be a poor
choice for therapy beyond the liver, since the bulk of the
virus is depleted in the liver. Whatever the intended target
tissue, a deeper understanding of Ad pharmacology reveals
that host sequestration mechanisms can result in only a fraction of the injected dose reaching its intended location. Here
we outline the obstacles that Ad encounters in vivo in order
to further inform the optimal design of Ad vectors.
Interactions with Blood Cells and Proteins
Upon intravenous delivery, evidence suggests that Ad5
interacts with a number of soluble proteins including natural
antibodies, complement [56] and blood clotting factors [4548]. These adsorptions likely occur immediately after virus
injection into the blood stream. Natural antibodies are circulating antibodies not induced by individual antigens, but encoded by the germline against common structures. Consequently, they are broadly specific, tend to have low affinity,
and provide naive hosts immediate defense against invading
pathogens like bacteria and viruses [57]. Natural antibodies
somewhat compensate for their low affinity with high avidity
and are predominantly IgM. Thus, natural antibodies also
serve as a potent complement activator, although Ad5 can
also bind directly to complement proteins from the classical
and mannan-binding lectin pathways [56, 58].
Studies have observed binding of complement protein C3
to the Ad capsid in the presence of factor B and factor D,
proteins involved in the antibody-independent alternative
pathway of complement activation [59, 60]. Interestingly,
complement protein C1q was shown to increase transduction
in CAR negative cells [61]. On the other hand, complement
binding to adenovirus is immunostimulatory, and can been
reduced by incorporating a complement-binding inhibitory
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peptide into fiber or pIX of the viral capsid [62]. Notably, the
mechanisms of complement activation in vivo have been
shown to be different than the mechanisms derived in vitro.
In vitro, antibodies are required for C3a binding and subsequent activation of the classical complement pathway. In
vivo, antibodies are not required for C3a binding, and activation can occur through both classical and non-classical pathways [58].
Complement binding can lead to clearance of the virus
via macrophage uptake, but recently it was also shown to be
involved with sequestration of the virus on erythrocytes.
Carlisle et al. found that Ad5 appeared to interact with complement factors which then act as bridge for binding to human complement receptor 1 (hCR1) on erythrocytes [63].
Murine erythrocytes displaying hCR1 significantly decreased
the amount of Ad5 able to transduce the liver in vivo (16
fold). Furthermore, CAR is also displayed on human, but not
murine, erythrocytes despite its role as a cell adhesion molecule. As erythrocytes are not productively transduced, they
can therefore act as a substantial sink for any systemicallyadministered Ad [64].
In addition to human erythrocytes, the majority of human
thrombocytes (72%) are also positive for CAR [65]. Although CAR has not been tested as the specific mediator for
the interaction, platelet pull downs and transmission electron
microscopy reveal that Ad5 binds directly to thrombocytes
and activates them [66]. The von Willebrand factor, one of
the proteins released during platelet degranulation, is implicated in causing platelet-leukocyte aggregates as well as the
widely observed phenotype of Ad5 induced thrombocytopenia [65].
Systemic Distribution of Adenoviruses
When delivered i.v. directly into the bloodstream, Ads
will be delivered to the heart via the inferior or posterior
vena cava, be pumped through the lungs, and then be sent to
the periphery via the aorta and arteries (Fig. 3A). Free or
bound virus can circulate through the body to encounter any
cell or tissue in contact with the blood. An intravenous (i.v.)
dose of Ad will likely first encounter the heart and lungs
before being distributed to the liver, spleen, and kidneys
(Fig. 3A). Furthermore, general endothelial cells lining the
vasculature throughout the body may theoretically be a huge
sink for any Ad serotype. While there is evidence that Ad5
and other serotypes infect endothelial cells, these interactions
do not appear to be particularly productive, perhaps due to
low levels of cognate receptors [67, 68]. To what degree
bulk endothelial cells differ from liver sinusoidal endothelial
cells (LSECs) in Ad interactions is unclear. Obvious differences relate to the ability LSECs to form fenestrations and to
pinocytose material (see below).
The body eliminates most compounds, including Ads,
through the natural filtering functions of the liver and kidneys. Water-soluble items can be removed by the kidney and
hydrophobic compounds are generally metabolized in the
liver for subsequent excretion in the gut or in the kidney.
While Ads can and do accumulate in a variety of organs, the
liver appears to be the principal sink for prototype Ad5 virus.
This filter function is demonstrated in elegant pharmacologic
studies in mice. At doses up to 4x1012 vp/kg of Ad5, ap-
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proximately 98% of injected virus is found in the liver 30
minutes after injection [69]. At this same dose, only about
1% of injected Ad5 can be found in either the lungs or the
kidney at this dose. If the dose is increased 4-fold, Ad5 in the
liver falls to 85% of injected dose and virus in the spleen and
lung rises to 6 and 5% of injected dose, respectively.
It should be noted that when normalized to organ weight
(i.e. specific activity instead of total activity) the spleen can
appear to express Ad5 nearly as well as the liver [70]. This
representation is helpful for understanding adenoviral biology, but may minimize the true effect of the virus in vivo
since the liver is substantially larger. Such analyses become
appropriate in terms of generating immune responses to Ad
or its transgene products, since total expression of the immunogenic epitopes is more relevant than specific activity
VECTOR SEQUESTRATION IN THE LIVER
Liver sequestration is remarkably fast as we demonstrated recently using near-infrared (NIR) fluorescent imaging in mice [71]. Ad5 was labeled with the NIR fluorophore
IR800 and injected i.v. into the jugular vein. By fast image
capture (250 millisecond exposures every 0.5 millisecond),
virus could be seen entering the heart within 500 milliseconds of injection. Within 7 seconds, the viral swarm was
observed in arterial outflow throughout the mouse. Virus
then returned from the periphery and began accumulating in
the liver. Within 3 minutes of injection, the bulk of virus
distribution was essentially complete with the vast majority
being localized to the liver and less so to the spleen and kidneys [71].
In humans, approximately 1.5 liters of blood is delivered
into liver sinusoids from the portal vein and hepatic artery
every minute for filtration (Fig. 3B, C, and D). Particulates
like Ad that enter liver lobules and their sinusoids encounter
Kupffer cell macrophages and LSECs that serve as gatekeepers for the liver (Fig. 3C and D). There is some evidence
that Ad5 that is ensnared on platelets, is trafficked to the
liver, and also likely trafficked to the spleen. Indeed, thrombocytes may deliver viral particles to resident liver macrophages, also known as Kupffer cells, within minutes of intravenous injection. Depletion of platelets prior to adenovirus
injection in one model was able to decrease the amount of
viral DNA in the liver [66]. In contrast, blood factor binding
or platelet binding to Ad5 was not found to contribute to
Kupffer cell uptake in other studies [56]. Therefore, it is
somewhat unclear whether platelets play a role in delivery of
Ad5 and other serotypes to liver Kupffer cells.
Viruses that escape both Kupffer cells and LSECs can
enter the space of Disse through fenestrations in the LSECs
(Fig. 3C and D). Once in the parenchyma, virions can interact with hepatocytes via evolved or captured cell binding
ligands to mediate transduction or liver damage depending
on serotype. Viruses that fail to infect hepatocytes after entry
into the space of Disse are presumably captured in the lymph
from the lobules and delivered to draining lymph nodes (Fig.
3D). If viruses are transcytosed (perhaps by engaging caveolin rather than clathrin entry pathways) they could theoretically be ejected on the other side of the hepatocytes into the
bile (Fig. 3D). The effects or level of virus distribution,
transduction, and infection from the lymph and bile of the
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liver remain largely unexplored. Given their likely delivery
to mucosal and immune cell education sites, these routes of
virus distribution may have profound effects on immune
responses against Ads and their transgene products.
Kupffer Cells
Kupffer cells (KCs) are the resident macrophage of the
liver and are essential in removing foreign particles and
pathogens from the blood stream (Fig. 3C and D). Although
they comprise only ~7% of liver cells, they estimated to account for 80-90% of all of the macrophages in the body [72,
73]. It has been estimated that liver Kupffer cells can sequester up to 98% of intravenously injected Ad5 vector in mice
[74]. These interactions are thought to be predominantly
phagocytic and non-productive for infection, since this uptake triggers massive destruction of virions and the Kupffer
cells [74, 75]. However, a small proportion of virions that
interact with Kupffer cells may enter by integrin binding to
mediate low level transduction of these cells [76]. For example, at very high doses of Ad5 (1 x 1011 PFU/kg), 70% of
hepatocytes and 15% of Kupffer cells expressed transgene
three days later [76].
Scavenger receptor A (SR-A) is a broadly specific scavenger receptor expressed on the surface of Kupffer cells that
is thought to recognize net negative or positive charge [56].
Injection of negatively charged polyinosinic acid, or poly(I),
into mice prior to injection of Ad5 transiently increased viral
circulation in the blood 10-fold; transgene expression increased in a variety of tissues by 5- to 15-fold [77]. The hy-
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pervariable region 1 (HVR1) on Ad5 hexon in particular has
large amounts of charged residues and has therefore been
implicated in Kupffer cell recognition [74]. On the other
hand, Kupffer cells in wild-type and SR-A knock out mice
appeared to take up similar amounts of Ad5, suggesting that
Kupffer cells have alternate or redundant mechanisms for
viral recognition [68].
Liver Sinusoidal Endothelial Cells (LSECs)
Liver sinusoidal endothelial cells (LSECs) are also a major component of the reticuloendothelial system (RES) although their role in phagocytosis of particles like Ad is underappreciated [78]. LSECs line the sinusoids of the liver
and represent ~25% of liver cells ([72] and Fig. 3C and D).
Like Kupffer cells, LSECs express scavenger receptors
SREC 1 and SREC-II that may be candidates for uptake of
Ad particles [79]. LSECs work in concert with Kupffer cells
to clear material from the bloodstream. Unlike Kupffer cells
that can engulf particles up to 2 m in diameter, LSECs remove particles under 230 nm in diameter by pinocytosis [78,
80]. Therefore, both cell types of have an overlapping ability
to remove Ads from the circulation, although an increase in
the effective diameter of Ad virions upon binding to other
circulatory factors may favor uptake by Kupffer cells. Interestingly, when Kupffer cell uptake was impaired, LSECs
were able to take up particles >1 m in diameter [80].
Sequestration of Ad by vascular endothelial cells is unclear,
although in situ experiments show that like LSECs they are
poorly transduced even at high doses [81].
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Fig. (3). Adenovirus delivery upon systemic injection. (a) Distribution of virion delivery including largest pharmacologic “sinks”. 1 =
Liver, 2 = Spleen, 3 = Kidney, 4 = Lung, 5 = Bloodstream. Schematic of viral migration from the blood stream into the parenchyma of liver:
(b) within the lobule structures of the liver and (c,d) within one lobule. (c) represents flow of virus from the triad to the central vein looking
down into the sinusoid. (d) represents permeation of virus from inside the sinusoid out into the parenchyma via fenestrations. (d) also shows
other pharmacologic paths virions may take including outflow in the the lymph and bile.
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Like Kupffer cells, LSECs are inefficiently transduced by
Ad5, showing no expression at <100 infectious units
(IU)/cell, and meager expression at >1000 IU/cell in vitro. In
contrast, 100% of hepatocytes are infected by Ad5 at 5
IU/cell. Similar results have been observed in vivo. For example in mice, no transduction of Kupffer cells or LSECs
was observed after injection of Ad5 [82].
The Effects of Host Species and Strains on Adenovirus
Pharmacology
The complexity and crucial differences in uptake of Ad5
by the liver is reflected in direct comparisons of transgene
expression in various inbred mouse strains. At a moderate
dose of 1 x 1010 vp Tao et al. demonstrated a ~400-fold range
of variation in Ad5 liver transduction in NCR nude,
C57Bl/6, BALB/c, C3H, and Rag-1 mice. Higher doses of 8
x 1010 vp, which test expression effects after exceeding the
Kupffer cell “threshold” show a different profile of expression in these mice, with a 30-fold range in variability [83].
Snoeys et al. determined that BALB/c mice take up ~6-fold
more Ad DNA in their non-parenchymal cells than C57BL/6
mice. When analyzed by cell type, they showed that BALB/c
mice sequestered ~20 times more Ad DNA in their Kupffer
cells than C57BL/6 mice after i.v. injection [84]. Conversely,
C57BL/6 mice took up more virus in their LSECs rather than
in their Kupffer cells. Interestingly, they found that the overall number of Kupffer cells between the two mouse strains is
not significantly different, suggesting that fundamental differences in the location, types, and/or density of receptors
responsible for Ad uptake may be significantly disparate
between animal strains.
Electron microscopy shows that LSECs form sieve plates
with fenestrations [85, 86] that allow Ads to reach the parenchyma of the liver and hepatocytes [87, 88] (Fig. 3). However, fenestration sizes can be highly variable between species: >150 nm for Sprague Dawley rats, 141 nm for C57Bl/6
mice, 103-105 nm for two strains of rabbits and 107 nm for
healthy human livers [72, 89].
These data have been used to propose that the effect of
Ad in humans may not be predicted by murine models.
While this may be the case, it should be noted that these fenestration measurements are mean sizes, not an absolute cutoff. For example, the mean fenestration size in healthy human livers were reported as 107 nm although diameters may
reach up to 240 nm in diameter [72, 89]. Indeed, in human
liver, more than half of the measured fenestrations exceeded
the diameter of Ad. These theoretical calculations are supported by human data. For instance, increases in liver enzymes are routinely observed when human patients have
been injected with replication-competent, replicationselective, or replication-defective Ad5 by intravascular injection or even after intratumoral injection [90-92], suggesting
that virus must be reaching hepatocytes in order to stimulate
such release.
Our original tests of Ad pharmacology were performed in
outbred mice to avoid the effects of inbreeding in favored
mouse strains [67, 70, 88]. As we have moved to evaluating
immune responses to Ad and its transgenes and utilizing
genetically modified mice, we have transitioned to working
in inbred strains or on different inbred genetic backgrounds
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[23, 93-96]. We have found that the genetic background of
the mice can have profound effects on the pharmacology of
Ad as evidenced by recent work in our laboratory. Comparisons of BALB/c, C57BL/6, FVB, 129, nude, and hairless
HRS mice demonstrate considerable differences in raw gene
expression in the liver after intravenous injection and after
manipulating the levels of Kupffer cells prior to injection
([94, 95] and unpublished data). The use of different strains
of mice may explain some diametrically-opposed results in
the literature particularly regarding the effects of Kupffer
cell depletion and why certain strains of mice will respond to
gene therapy and others will not. Until the key biologies are
identified that control these pharmacologic effects and how
they apply in humans, the best approach is to test Ad pharmacology in several strains and in other species.
Beyond the Liver
The discussion above has focused on what we currently
consider the “biggest” initial steps and barriers that adenoviruses encounter after an intravenous injection. Beyond the
blood, vascular endothelial cells, and the liver Big Three (i.e.
Kupffer cells, LSECs, hepatocytes), there are of course other
cells within the liver that likely encounter and interact with
adenoviruses (i.e. liver dendritic cells, stellate cells, lymphocytes, etc.). Beyond the liver, we know that a smaller, but
significant fraction of Ad lands in the spleen, kidneys, and
lungs after intravenous injection (Fig. 3A). Indeed, different
serotypes of Ad are likely to permeate to many sites that we
currently do not have the sensitivity to track (other organs,
tissues, lymphatics, etc.). These locations also impact the
pharmacology and, importantly, immune responses against
Ads and their transgenes.
ADENOVIRAL VECTOR DETARGETING
The vast majority of early work to modify Ad tropism
was directed at retargeting the virus to new receptors. Subsequent work aimed to detarget Ad from its cognate in vitro
receptors. When these efforts have been applied in vivo, they
have generally failed for lack of decent targeting ligands and
because of limited understanding of Ad pharmacology in an
intact body. The revolutionary observations concerning the
depletion of Kupffer cells by Ad and the unexpected effect
of clotting factors on Ad pharmacology have opened up a
new area to apply effective detargeting strategies. We hypothesize that once we can detarget the wrong cells effectively in vivo, then retargeting with new ligands may begin to
succeed. However, we may need to know all of the cells and
proteins that are mistargeted before detargeting will be optimal.
Evading Blood Proteins and Cells
After intravenous injection, Ads bind proteins and cells
in the blood. As some of these interactions are ligandreceptor driven (i.e. hCAR and hCR1 receptors on erythrocytes, etc.) the use of alternate serotypes may attenuate some
effects. Other approaches are to genetically-delete these
evolved viral ligands to specifically detarget CAR, CD46,
integrin, and other interactions [68].
Another approach to evade interactions is to coat Ads
with linear or looped hydrophilic polymers like polyethylene
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glycol (PEG) and poly-N-(2-hydroxypropyl) methacrylamide
(HPMA) ([64, 67, 69, 70, 74, 88, 93, 97-111] and see below).

for more distant delivery, this process is highly inflammatory
and Kupffer cell evasion, rather than destruction, may be a
preferable method [75, 121].

Polyethylene glycol (PEG) is a stable, uncharged, hydrophilic, and synthetic polymer widely used in food and drug
industries. Made up of repeating units of ethylene oxides
(CH2-CH2-O-) it can be synthesized in multiple shapes (e.g.
branched and linear) and varying lengths (resulting in molecules up to 40 kDa in size). PEG can be manufactured with
functional groups on their one or both of their termini, resulting in its use as a versatile chemical modifier for adenovirus.
Heterobifunctional PEGs have functional groups on either
end of the molecule. This enables its use as a linker molecule, or can be useful in detection of PEGylated virions. For
instance, heterobifunctional PEG such as Alexa488-PEGmaleimide can be covalently linked to cysteines on the capsid of Ad5, thus tagging it with a fluorescent marker [112].

To what degree other Ad serotypes are trapped in the
liver is still under investigation. Despite their close homology, preliminary comparison of species B Ad11 and 35, species C Ad5 and 6, and species D Ad26 and 48 for predosing
demonstrated that Ad5 was by far the most effective at enabling a subsequent dose of Ad5-luciferase to transduce hepatocytes ([122] and data not shown). While this suggests that
other Ad species may not be adsorbed by Kupffer cells, these
other serotypes may be encountering sinks of their own,
since they are not entirely neutral and some actually cause
lower subsequent expression in hepatocytes. Closer examination of Ad6 suggests that it may evade Kupffer cells much
better than Ad5 [14, 94]. Indeed, Ad5 and Ad6 are substantially better at liver-directed gene therapy than their family
members Ad1 and 2 [14].

HPMA is a hydrophilic polymer composed of an unreactive carbon chain backbone with diglycyl side chains. Approximately 10 amino-reactive 4-nitrophenoxy groups are
incorporated into these side chains per 100 monomers of the
backbone. Thus, HPMA is a multivalent polymer and can
interact with an Ad capsid at multiple locations like a zipper.
Both of these polymer approaches prevent interactions of
Ad with a variety of blood proteins and cells. For example,
PEGylation of Ad5 blocks CAR binding, thereby eliminating
interactions with any CAR-expressing cell [70]. For example, PEGylation and/or HPMA modification blocks binding
and activation of platelets, red blood cells, and endothelial
cells by Ad5 [64, 67, 113]. These effects in the blood or tissues have substantial abilities to reduce innate immune responses and liver damage after i.v. injection of Ad. However,
random polymer modification can inhibit virus function [70].
Therefore, approaches to target PEGylation to specific sites
on Ad by using maleimide-PEG to react with inserted cysteines may reduce interactions with blood cells while preserving virus activity [95, 105, 106, 114].
Evading the Liver: Kupffer Cells
In mice, 98% of a low dose of Ad5 is found in the liver
30 minutes after i.v. injection [69] and little hepatocyte transduction is observed due to sequestration of Ad5 by Kupffer
cells and LSECs. This sequestration can be overwhelmed
with higher doses [115], but this also increases toxic side
effects. An alternate approach is to "predose" the system by
injecting gadolinium chloride, chlodronate liposomes, or
high doses of Ad5 to saturate and kill Kupffer cells before
injecting the therapeutic or reporter virus [74, 116-120]. For
example, predosing mice with Ad5 before injection of Ad5luciferase increases hepatocyte transduction 44-fold [120]).
Therefore, by eliminating Kupffer cells (and likely other
cells like LSECs) with a first dose of Ad5, more functional
virus is available to reach distant sites. In this case, when
using a hepatocyte-tropic Ad5 the next downstream functional targets are hepatocytes that are effectively transduced
by the virus. When performing oncolytic therapy against
distant tumors, predosing increases the ability to kill tumors
systemically [120]. Manickan et al. showed that in
sequestering Ad5 virions, Kupffer cells themselves are destroyed [75]. Therefore, while liberated virions can escape

PEGylation of Ad also appears to be an effective means
to detarget Kupffer cells. Random conjugation of succinimide-activated NHS-5 kDa PEG to Ad5 mediated
marked reductions in Kupffer cell uptake in mice [70]. Interestingly, while this reduced many side effects (IL-6, thrombocytopenia, etc.), PEGylation did not appear to reduce uptake of virus into splenic cells (unpublished observations).
Follow up testing of this approach with replication competent oncolytic Ad5 with different-sized NHS-PEGs (5, 20,
and 35 kDa NHS-PEG) showed that 5 kDa PEG increased
hepatocyte transduction, presumably by detargeting Kupffer
cells [88, 107]. In contrast, larger PEG appeared to detarget
both Kupffer cells and hepatocytes as evidenced by reduced
liver expression. One possible cause for this reduction may
lie in the failure of virions to access hepatocytes via fenestrae, due to the increase in virion diameter upon PEGylation.
This dramatic increase in viral expression is not dependent
on complete coating of the viral capsids, but could be replicated with specific conjugation of 5 kDa PEG into only the
HVR5 loop of Ad5 hexon [114]. Subsequent systematic targeted PEGylation of HVR1, 2, 3, 4, 5, 6, and 7 in Ad5 demonstrated that shielding HVR1, 2 and 5 produced up to 20
fold increases in hepatocyte transduction whereas modification of the other HVRs had less effect [95]. Given that
Kupffer cells are thought to phagocytose Ad5 via scavenger
receptors, shielding the multiple negative charges
particularly in HVR1 with this hydrophilic polymer likely
mediates much of the protective effects on the virus.
Evading the Liver: Hepatocytes
Based on the Ad5 prototype in mice, it appears that much
of intravenously injected virus is sequestered by Kupffer
cells and possibly by LSECs. Some fraction of any injected
dose can escape these cells to go on to transduce hepatocytes
or go further to infect extra-hepatic tissues. Kupffer cell depletion or evasion allows Ad5 virus to enter the next viral
sink, which for this hepatotropic virus are hepatocytes,
which yields productive transgene expression. If another Ad
serotype is used that is less hepatotropic (e.g. due to lack of
FX binding), then hepatocytes may not be the next viral sink,
but it may be another tissue downstream. It appears that approximately 50% of human Ad serotypes do not bind FX
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[47], so these may be good platforms for hepatocyte evasion
provided they do not infect the cells by other mechanisms.
Gene delivery by Ad in the liver occurs because of productive expression in hepatocytes [75, 83, 116-119, 123].
One method of hepatocyte detargeting uses pharmacologic
ablation. In this case, warfarin can be used to inactivate vitamin K-dependent blood clotting factors and reduce Ad5
delivery to hepatocytes [120, 124]. While this is feasible in
mice, achieving such low levels of FX in humans would
likely be prohibitive given its effects on clotting. Modeling
based on cryo-EM suggested that FX may interact with hypervariable (HVR) loops 3, 5 and 7 on Ad5 [125]. Similarly,
insertion of peptides such as the biotin acceptor peptide
(BAP) into HVR5 of replication competent Ad5 has demonstrated reduced expression of the luciferase transgene and
increased expression in orthotopic tumors, thus extending
survival [126].
While polymer modification of Ad may be expected to
block Ad5-FX interaction, PEGylation appears to block Ad5
liver transduction directly. Indeed, random NHS PEGylation
and targeted maleimide PEGylation both appear to preserve
the ability of FX to bind to Ad5 virions [88, 95]. Given that
RGD-integrin interactions appear functional on hepatocytes
[68] and that integrin interactions are preserved after PEGylation [70], this interaction may be involved in maintaining
hepatocyte transduction in the case of small PEGs. In contrast, large PEGs (20 kDa, etc.) may make the virus too big
to cross fenestrae and/or use integrin associations, and therefore they may be used as a means to detarget hepatocytes.
Evading the Liver: LSECs
Kupffer cells are thought to be the biggest sink for Ad5
in the liver, depletion of them by predosing surprisingly does
not reduce the number of vector genomes in the liver [120,
127]. Combined predosing and warfarin improve oncolytic
killing of distant tumors after i.v. injection, but these two
detargeting strategies nevertheless do not significantly decrease viral genomes in the liver or increase viral genomes in
the tumor at short time points [120]. In contrast, when Koski
et al. treated mice with warfarin to deplete vitamin K dependent blood factor interactions, anti-platelet antibodies,
and Kupffer cell scavenger receptor blockers into mice prior
to Ad injection, the combination of these treatments yielded
an 81% increase in tumor to liver ratio of virus [128].
These data suggest that virus may be sequestered by
other cells of the liver. To address this, Shayakhmetov's
group tested Kupffer and hepatocyte detargeting strategies
combined with integrin detargeting by ablation of the RGD
motif in Ad5 [68]. They showed that no single intervention
by itself fully detargeted the virus from the liver. Rather,
only when all three interventions were applied were significant reductions in viral sequestration observed. In particular,
ablation of integrin binding appeared to detarget LSECs and
hepatocytes, emphasizing the roles of both Kupffer cells and
LSECs in viral trapping. Therefore, detargeting all three cell
types (and maybe more) appears important to liberate virus
for systemic delivery.
Since PEG and HPMA polymers tend to reduce proteinprotein interactions, it is not surprising that coating Ads with
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these hydrophilic polymers also has effects on interactions
with endothelial cells. For example, coating Ad5 with 5 kDa
PEG reduces infection and activation of human endothelial
cells in vitro [67]. In vivo, PEGylation of Ad5 also reduces
interactions with liver LSECs as evidenced by reduced
upregulation of E-selectin messenger RNA [67].
Evading Other Cells and Tissues
Progress is being made to avoid Kupffer cells, LSECs,
and hepatocytes in the liver. As this predominant adenoviral
trap is avoided, it is likely that new ones will surface. Currently, the spleen appears to be the next biggest pharmacologic sink, at least in mice [70]. The spleen appears to trap
viral genomes approximately 3 times more than the liver in
terms of viral to host genomes. Again, this is specific activity
per unit tissue, so total amount of expression and viral genomes is profoundly higher in the liver.
Splenic uptake likely occurs due to entrapment on blood
cells and direct capture by macrophages. For instance, after
i.v injection in mice the weight of the spleen increases 200%
over the following 7 days [67]. When Ad5 is injected i.v.
into splenectomized mice, the level of virus in the blood increases approximately 300% [67]. In the absence of a spleen,
innate immune responses are also reduced 25% suggesting
roughly that one quarter of the response is generated or
modulated in this organ.
Beyond the spleen, the lung is a likely sink by direct infection and also by the curious effect Ad5 (and perhaps other
serotypes) has on Kupffer cells. Ad5 kills Kupffer cells
within minutes of uptake [75] and ~4 hours later, the dead
Kupffer cell fragments are released into the circulation. Like
most large aggregates, these Kupffer cells are filtered from
the circulation by the lungs and Ad-infested Kupffer cell
remnants can be found in pulmonary capillaries. To what
degree Ad remains active for gene delivery remains to be
determined, particularly when replication-competent instead
of replication defective virus is used. Indeed, Smith et al.
have shown that cirrhotic rats actually suffer from substantially higher lung toxicity after Ad dosing than normal animals [129]. Therefore, evading Kupffer cells altogether may
reduce transfer of virus to sites like the lung.
PROTECTING ADENOVIRUS FROM THE IMMUNE
SYSTEM
Host sequestration, viral traps, and pre-existing immunity
necessitate the use of vastly larger doses of intravenously
delivered vector for liver-directed or systemic therapy. However, as Ad capsids are known to be potent immunogens,
delivering high doses of any Ad serotype will likely provoke
hemagglutination, the formation of immune-complexes, activation of complement, recruitment of immune cells, the
rapid and wide release of proinflammatory cytokines, and
thus vigorous tissue damage (discussed in our original review). Given that adenoviruses are infectious agents, humans
have widespread pre-existing immunity to different Ad serotypes. Similarly, vector induced immunity upon use as a
therapeutic agent can prevent its use in the same person more
than once. Therefore, we discuss the effect of innate and
adaptive immune responses against human and non-human
Ad vectors.
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Evading Neutralizing Antibodies and Immune Responses
Upon primary exposure to Ads, an immunocompetent
host will generate innate immune responses within hours of
infection and robust adaptive responses are generated over
the course of two weeks. Therefore, Ad vector administration in the naïve host produces transgene expression that
generally peaks within days of injection after which expression is eliminated within two weeks due to CTL responses
against Ad, Ad-infected cells, and/or transgene epitopes
[130].
Upon secondary exposure to an Ad serotype, memory T
cells expand a population of CTL effector cells more rapidly
than in the first exposure to swiftly eliminate Ad-transduced
cells. Furthermore, capsid-directed antibodies can neutralize
a large fraction of virions to drastically blunt the level of
transgene expression that would normally occur. The degree
of neutralization can depend on the site of administration.
Intravenous injection of Ad exposes it to large concentrations of systemic antibodies that efficiently decrease transduction [131]. In contrast, if the virus is injected at surfaces
with lower levels of persistent antibodies (i.e. nasally, orally,
vaginally), the systemically-immune host may not neutralize
the virus effectively [132]. Similarly, injection into an isolated tissue (i.e. a tumor) or into an immunologicallyprivileged site (i.e. the eye) can prevent or reduce antibody
neutralization.
The ability to cross-neutralize another Ad is directly dependent on the ability of the polyclonal Ad antibodies to
bind to conserved epitopes on the Ad surface. For example,
neutralizing antibodies generated against Ad5 are most effective at neutralizing Ad5, but can also partially neutralize Ads
of the same species. T cell responses can be more broadly
cross-reactive, since functional protein structures are less
variable. For example, amino acids involved with hexon
trimer structure and interactions with other capsomer proteins are conserved even between Ad species and are good
targets for major histocompatibility complex (MHC) class I
and class II. On the other hand, HVRs on hexon are not intrinsic to function and widely vary to evade other serotypes’
neutralizing antibodies.
As the most abundant capsid protein, most neutralizing
antibodies are directed at hexon. Hexon-targeted antibodies
appear to neutralize the virus not by blocking viral entry but
instead by blocking microtubule transport of the virus to the
nucleus after it escapes endosomes [133]. The second most
prevalent neutralizing antibodies are against Ad fiber [54,
134]. These can block interactions with receptors or by targeting the virus to antigen-presenting cells [135]. Immune
system targeting of these two proteins is also reflected Ad
fiber and hexon protein diversity since a comparison of Ad
serotypes shows that hexon and fiber are most variable even
within one species of the virus [13, 37].
Multiple studies have shown that most humans are immune to Ad5, although levels of immunity are geographically variable and differences in testing for neutralization
does not lend itself to ideal comparison. According to some
estimates, 30-50% of Americans, 60% of Japanese, and 4575% of people from Europe (Italy, UK, Netherlands, and
Belgium) have pre-existing immunity to Ad5 [136, 137].
Ad5 seroprevalence can even reach as high as 100% of peo-
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ple in regions such as Brazil, sub-Saharan Africa and India
[22, 138-140].
Ad seroprevalence within populations is strongly correlated with increasing age, presumably as a result of natural
infections [139, 141]. One exception is infants below the age
of 6 months, who can receive passive but transient immunity
against Ad5 through maternally derived antibodies [139].
This seroprevalence data presents a clear “window” of low
anti-Ad immunity in children between the age of 6 months
and 7 years, and may signify the ideal time for Ad based
therapies.
Delivery of an Ad in a pre-immune host may not only
attenuate therapy, but also have unexpected effects. A recent
example is the now infamous Merck STEP HIV Vaccine
trial. In this Phase II clinical trial, first generation (FG) E1deleted Ad5 vaccines expressing gag, pol, and nef were used
in individuals at high risk of HIV-1 infection as a T cell generating HIV vaccine strategy [142]. While this trial showed
some positive immunologic effects, it was halted after failing
to decrease HIV infection. Unexpectedly, early data from the
STEP trial suggested that uncircumcised individuals with
higher titers of pre-existing antibodies against Ad5 also had
higher rates of HIV acquisition than volunteers with low Ad5
antibodies [142-144]. Based on this, Ad5-based vaccines fell
out of favor [145-147].
Tests to understand STEP trial effect suggested that prior
immunity to Ad5 followed by exposure to Ad5 could induce
stimulate a population of CD4+ T cells that might become
substrate for HIV infection [148]. However, further investigation has failed to demonstrate any true correlation between
pre-existing immunity and likelihood of HIV infection [140,
149, 150]. Follow up of STEP vaccinees shows that there is
no longer a statistical difference in HIV acquisition between
groups with high or low antibodies vs. Ad [142]. Prior immunity to Ad5 in a parallel Ad5 trial called the Phambili trial
had no effect on HIV acquisition [142]. Finally, a recent case
control study shows that immunity to Ad5 does not pose
increased risk of HIV infection [140].
Therefore, it is now unclear if the STEP trial effect was
real or was a transient effect. Other Ad vaccines, such as the
live attenuated Ad4 and Ad7 vaccines for military recruits
are considered so safe that they are again in production as
replication-competent vaccines [151].
Adenovirus Serotype-switching to Evade the Immune
System
One approach to evade neutralizing antibodies is to “serotype switch” the vector by changing the Ad serotype carrying genes with each administration [152]. This approach
markedly increases prime-boost with Ad vaccines as demonstrated for HIV vaccines [21, 153-155]. Because of their low
cross-reactivity and seroprevalence in humans, chimpanzee
adenoviruses Ad-C68, 6, and 7 have been studied for vaccine
purposes. Ad-C68 was shown to be effective at inducing
anti-rabies neutralizing antibodies and may be capable of
inducing anti-HIV-1 gag CTL immune responses [21, 156].
Santra et al. confirmed that simian Ads C7, C68 and chimeric C1/C5 were capable of inducing immune responses in
the presence of pre-existing immunity and could be used in
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prime/boost immunization strategies [157]. In addition to
their use as vaccine vectors a simian adenovirus ChAd3 was
shown to be effective at expressing carcinoembryonic antigen (CEA) and was as robust as huAd5 at breaking tolerance
and successfully overcoming tumorigenicity in the presence
of huAd5 pre-existing immunity [158].
Liu et al. explored the use of a recombinant human serotype 26 adenovirus as a vector for a T-cell based anti-SIV
vaccine. A further advantage of Ad26 was that it was only
found to have a 21% level of seroprevalence in Sub-Saharan
Africa, a region in desperate need of an HIV-1 vaccine [22].
Using a heterologous prime/boost of Ad26 and Ad5 expressing SIV gag they were able to show a 1.4 and 2.4 log reduction in peak and chronic viremia levels, respectively [159].
Ad48 was found to have a seroprevalence of only 3% in the
same region [22]. In another study, the hexon hypervariable
regions (HVRs) of Ad5 were replaced with the HVRs of
Ad48 hexon. This new Ad5HVR48 virus expressed SIV
Gag, Pol, Nef and Env and immunized macaques were found
to have lower peak and setpoint viremia levels [160].
The vast majority of work with adenovirus vectors has
utilized first generation Ad (FG-Ad) vectors that are typically deleted for their E1 and E3 genes (see [12]). FG-Ad
vectors carry 17 Ad protein open reading frames (ORFs) that
can be expressed and targeted by anti-Ad T cell responses
[161, 162]. In contrast, in helper-dependent adenoviral (HDAd) vectors, all viral ORFs are deleted [163-165]. No Ad
proteins are produced in HD-Ad vector-transduced cells
thereby evading T cells responses that can kill transduced
cells [163-165]. This reduced immunogenicity and reduced
liver damage allows for transgene expression in mice and in
baboons over years [8, 166-168]. The HD-Ad system is also
uniquely suited to serotype switching, since Ads of the species can cross-package each other’s genomes. HD-Ads therefore give the opportunity to evade both anti-Ad T cell responses and Ad neutralizing antibodies. Their low immunogenicity not only increases their safety, but also increases
their persistence in vivo. We recently studied the utility of
serotype switching HA-Ads 1, 2, 5 and 6 that expressed HIV
Env gp140 [23] to show that serotype switching in both mice
and rhesus macaques boosted anti-HIV immune responses. A
subsequent challenge of the HD-Ad serotype switch immunized macaques resulted in impressive immune control of
viremia in SHIV-SF162P3 challenged animals with 2 – 10
fold decreases in peak viremia with set-point viremia levels
~4 logs lower [169].
Polymer Modification of Ads to Evade Immune Responses
An original attraction of polymers like PEG for Ad coating was to protect it from neutralizing antibodies [98, 101,
102]. When tested in mouse models, PEG and HPMA polymers are able to protect Ad from pre-existing and vectorinduced neutralizing antibodies to allow multiple administrations into immune recipients [93, 98, 101, 102]. Ad PEGylation also reduces the production of new antibody and cellular
immune responses against Ad proteins [101].
While PEGylation does cover the virus with as many as
15,000 PEGs, it does not completely shield the virus and
PEGylated vectors recover only 10% of normal vaccine ac-
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tivity in the face of anti-Ad antibodies ([93] and data not
shown). In addition, the negative effects of random PEGylation on virus transduction can mitigate the benefits of antibody shielding. For example, when we tested succinimideactivated NHS-PEG for gene-based vaccination with Ad, this
random PEGylation ablates CAR-mediated transduction in
vitro and reduces in vivo transduction after intramuscular
(i.m.) and intranasal (i.n.) vaccination by 50 to 90% [93].
This loss of activity by i.m. and i.n. routes differs markedly
with the retention of in vivo transduction after i.v. injection
[70, 88, 107]. This difference is likely due to loss of needed
CAR binding by i.m. and i.n. transduction as compared to
FX-mediated transduction after i.v. injection.
One possible solution to this conundrum is the use of
targeted PEGylation of Ad [95, 105, 106, 114]. These targeted PEG vectors not only retain full in vitro transduction,
but targeted PEGylation of Ad at HVR1, 2, 5, and 7 actually
increases transduction after i.v. injection up to 20-fold [95].
To what degree polymer modification will protect viruses
from antibodies in vivo remains to be demonstrated in primeboost systems.
While there is some question of exactly how well polymers can protect virus from neutralizing antibodies, there is
good evidence showing that PEGylation can blunt many of
the innate immune responses against Ad [70, 170-172].
When injected i.v. into mice, PEGylation reduced innate
immune responses as evidenced by a 90% reduction in IL-6
over 48 hours [70] and IL-12 and TNF-alpha levels were
reduced three- and seven-fold, respectively [170]. In baboons, PEGylation reduced IL-6 3-fold, IL-12 by 50% [172].
Notably, PEGylation of Ad also reduces uptake of the virus
into antigen-presenting cells including macrophages and
Kupffer cells [70]. It also inhibits complement activation by
Ad5 [58].
ADENOVIRAL VECTOR RETARGETING
A better understanding of the sinks that absorb adenoviruses is crucial to retargeting these vectors to novel receptors
and increasing its therapeutic success. Our earlier review and
several others have discussed a number of strategies for vector retargeting which is crucial for both targeted gene therapy
and oncolytic purposes [12, 173-175]. Below, we highlight
new areas of Ad retargeting approaches that have been applied since the last review.
Peptide Inserts/Ligands/Linkers
The selection of targeting peptides from phage libraries
and their insertion into the viral capsid has been reviewed in
previously [12, 176]. These methods were unpredictable with
regard to whether peptide insertions would be tolerated by
the virus and retain their specificity. One approach to circumvent these problems involved selecting peptides from a
bacteriophage library that displayed random peptides in the
context of the Ad fiber HI loop, into which it would later be
cloned [177]. More recently, Ad peptide libraries have been
created in which random peptides are cloned directly into the
Ad capsid. In this way, functional virions can be directly
selected [178-180]. This technique was modified to accommodate the insertion of peptides with known affinity for cellular targets. Lupold et al. designed an Ad peptide library
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that had a constant binding peptide insert flanked with random linker sequences [179]. Virions could then be selected
for functional virus with retained binding specificity [181].
Although these Ad libraries could theoretically contain up to
109 unique peptides, current techniques to produce actual Ad
virions have only yielded library sizes of up to 2 x 105 [178,
179]. This imposes a significant restriction of the size of
peptides that can be screened as ligands. For example, a 105
peptide library in Ad can represent only four amino acidlong random peptides. In contrast, a 1010 peptide library on
bacteriophage can represent seven amino acid peptides (reviewed in [176]).
The success of peptide insertions for targeting is not only
dependent on the peptides, but also on their location on the
capsid. Ad peptide libraries are currently limited to fiber
insertions. The generation of pIX or hexon based Ad peptide
libraries may yield viruses that can take advantage of low
affinity, high avidity interactions. The recent high resolution
x-ray crystal and cryo-EM based structures of adenovirus
may provide new insight into other regions of the virus that
may tolerate modification for targeting [182-184].
Targeting adenovirus through the incorporation of high
affinity proteins like antibodies has been hampered by both
the large size of antibodies and improper folding of antibodies in the reducing environment of the nucleus where Ad is
assembled. To circumvent this incompatibility, molecular
adapters have been designed to bind to the Ad capsid outside
of the context of the nucleus. The first such adapter consisted
of a soluble form of CAR (sCAR) fused to targeting molecules like FGF-2, EGF [185], carcinoembryonic antigen
(CEA)[186, 187], and folate [188, 189]. More recently, another targeting adapter molecule consisting of the GLA domain from FX fused to single-chain antibodies was developed [190]. The FX fusion protein binds to hexon, and therefore has 240 binding sites as opposed to the 12 available
fiber proteins available to sCAR on the viral capsid. By binding to the HVR of hexon, native FX binding is reduced and
enables detargeting from the liver. Another possible benefit
of this technique is that it may allow improved spread of
virus in an oncolytic setting since targeting is not affected by
excess fiber production [190]. A major hurdle to this targeting method is that the adaptor molecules rely on noncovalent protein-protein interactions for their conjugation to
the Ad capsid, which are generally considered too weak in
vivo. Naturally occurring antibodies or CAR receptors could
compete for Ad binding and displace the molecular adaptors
from the capsid, abolishing the vector targeting activity.
In a third adapter molecule strategy, ankyrin repeat proteins (DARPins) have been designed to bind to fiber with
low nanomolar affinity [191-193]. DARPins are cysteineless alternatives to antibodies that consist of helical repeats
containing protein interaction surfaces. A DARPin library
was created and used to select DARPins specific for both
fiber and the target protein HER2. Fusion molecules of fiber/HER2 binding DARPins can be produced in E. coli and
have been used to target adenovirus to HER2 positive cells.
Further study will be needed to determine if these adapter
proteins will have any utility in vivo [194].
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SUMMARY
As research in Ad biology progresses, we begin to appreciate that vector pharmacology is less reliant on direct receptor binding and more influenced by complex interactions
between virus and host. Ad engineering efforts have generally been concerned with targeting vectors to an intended
location, and recent research demonstrates the paradigm shift
from fiber to hexon modification. In vivo, the interactions of
hexon and blood factors can be harnessed for liver-directed
gene therapy. Conversely, this same interaction can be a considerable viral sink for the purposes of therapy beyond the
liver.
Our growing understanding of Ad biology suggests that
Ad encounters progressive viral sinks in addition to blood
factors, such as interactions with circulating cells, antibodies,
and complement. More formidably, organs like the liver trap
enormous doses of therapeutic vector particles, yet even this
sequestration is partitioned into regions such as hepatocytes,
Kupffer, and endothelial cells. Here we summarize not only
the obstacles Ads face in vivo, but also strategies that have
been used to evade them. It has become clear that direct targeting strategies may have significantly increased success
when detargeting strategies are applied in combination.
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